CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Analyst Ratings
USA - NASDAQ:CMMB - US16385C2035 - ADR
2.67 USD
+0.04 (+1.52%)
ChartMill assigns a Buy % Consensus number of 84% to CMMB. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 30.26. This target is 1033.33% above the current price.
CMMB was analyzed by 9 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about CMMB.
In the previous month the buy percentage consensus was at a similar level.
CMMB was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-27 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-16 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-02-20 | Maxim Group | Maintains | Buy -> Buy |
| 2024-11-15 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-05-13 | Maxim Group | Initiate | Buy |
| 2024-05-06 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2024-03-08 | Oppenheimer | Maintains | Perform -> Perform |
| 2023-12-19 | Roth MKM | Reiterate | Buy |
| 2023-10-06 | Roth MKM | Initiate | Buy |
| 2023-06-07 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2023-04-18 | Oppenheimer | Maintains | Outperform |
| 2022-03-10 | Oppenheimer | Maintains | Outperform |
| 2021-12-07 | Aegis Capital | Initiate | Buy |
| 2021-05-26 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-05-07 | Oppenheimer | Initiate | Outperform |